SHARE

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) has received a change in its price target from analysts, the stock now holds an average rating of buy, from 6 analysts. The company most recently filed its 4Q2015 report, with a profit of $69.7 million. It is important to note here that the company had a loss for the same period, in the preceding year. Consequently, the EPS for 4Q2015 stood at $0.86, with the adjusted EPS at $0.62. THLD has successfully surpassed analyst expectations of -$0.11. However, the biggest surprise was in company revenues, which stood at $65.9 million, compared to analyst expectations of $4.5 million.

Osiris Therapeutics, Inc. (NASDAQ:OSIR) has been observing a delay in the filing of its 4Q2015 report. The company has also been experiencing various setbacks, which has adversely affected the stock. However, the biggest red flag around the stock is the fact that the company would not be able to release its earnings report, during the 15-day extension period. This puts the stock at risk of being delisted.

The stock recently received an average rating of hold from analysts and brokerages. An analyst at Brean Capital revealed that his brokerage doubts the ability of Osiris to remedy the current issues and release any reliable financial statements. However, the analyst did still maintain that the company would report a 13% revenue growth during the year. Furthermore, the company’s 3Q2015 had included 1 time sales worth $7.6 million, which will have a negative impact on revenue growth in future filings.

Aldeyra Therapeutics Inc (NASDAQ:ALDX) has announced that it would be holding a conference call for its 4Q2015 earnings report and guidance on March 30, 2016. Analysts at Zacks believe that Aldeyra can beat earnings estimates for the quarter, this time. This is based on the fact that the stock has been experiencing a favorable revision of earnings estimates. Zacks is yet to make any such revisions, while other analysts expect the company to report -$0.16 in EPS, compared to -$0.30 from Zacks.

LEAVE A REPLY